The activity and epithelial tropism of the human papillomavirus type 18 P105 early promoter, which directs the synthesis of the E6 and E7 transforming genes, are controlled by cis elements included in the viral long control region. To identify potential cellular regulators of this promoter, we mutagenized one or both of the 5'-TGACTAA-3' cis elements capable of interacting with the AP1 transcription factor, which is composed either of homodimers or heterodimers of the Jun products or of heterodimers of Jun and Fos. Mutation of both elements completely abolished P105 promoter activity in human keratinocytes. We show that either AP1 site can interact efficiently in vitro with any of the three different Jun products as heterodimers with c-Fos. However, in nuclear extracts prepared from human keratinocytes, JunB was the predominant Jun component bound to the DNA probe containing this cis element. These results implicate JunB as an important factor in human papillomavirus type 18 transcription in keratinocytes and strongly suggest a potential role of this Jun gene product in the tissue-specific transcription of the genital papillomaviruses. 
Several human papillomaviruses (HPVs), including types 16, 18 , and 33 , are associated with anogenital carcinomas. In many cases, the malignant cells express the viral transforming functions, which are encoded by the E6 and E7 open reading frames (42, 46, 48) . These products are together necessary and sufficient for immortalization of human normal keratinocytes in culture, although in certain conditions, E6 alone or E7 alone can immortalize keratinocytes (2, 22, 32) .
Transcription of the HPV-18 E6 and E7 RNAs initiates upstream of the E6 open reading frame at nucleotide (nt) 105, very close to the E6 initiation codon (42, 46, 50) . The PI05 promoter has been shown to exhibit stringent cell type specificity, since it can function only in certain human epithelial cells. These include human keratinocytes and cervical carcinoma cell lines, two cell types commonly used to study transcriptional regulation of genital papillomaviruses. A transcriptional enhancer, contained in a 200-bp subfragment of the upstream regulatory region, situated 230 bp upstream of the P105 initiation site and containing one AP1 binding site, also exhibits cell specificity, although not as stringently as does the whole promoter region (4, 17, 49, 52) .
Binding sites for several nuclear proteins have been identified in the HPV-18 and HPV-16 regulatory regions by DNase I footprinting experiments (17, 21, 38, 47) . Some of the protected sequences could be attributed to known factors either by sequence homology or by binding competitions. Among these known factors are the ubiquitous NFl/ CTF, OCT1, AP1, and SP1 transcription factors. cis elements interacting with these factors are found in the regulatory regions of HPV-16, HPV-18, and HPV-11, although at different locations and in varying numbers. Functional analyses to investigate the role of these elements in the cell-type-specific transcription of this class of virus have indicated that these ubiquitous transcription factors may all be involved in a very complex interplay. Notably, an impor-* Corresponding author. tant role of AP1 in the enhancer activities of the HPV-16 (9, 12) and HPV-18 (34) regulatory regions has been suggested.
The HPV-18 regulatory region contains two putative API binding sites, as shown by footprinting experiments using nuclear extracts from various cell types (17) . The two binding sites, located at nt 7795 and 7613, at positions -171 and -349 with respect to the P105 start site, contain identical sequences 5'-TGACTAA-3'. Although in inverted orientations, these sequences are closely related to the AP1 binding consensus tetradecanoyl phorbol acetate (TPA)-responsive element (TRE) sequence. Binding to these sequences could be abolished by an excess of a DNA probe containing the consensus TRE sequence 5'-TGACTCA-3' (17) . Sequences similar to that of HPV-18 and binding AP1 (PEA1) were found in the polyomavirus or simian virus 40 (SV40) regulatory regions, where they play a crucial role in the control of viral transcription as well as replication (28, 31, 35) . AP1, which mediates transcriptional stimulation by tumor promoters such as TPA, is a heterodimer of the products of two proto-oncogenes, jun and fos. Both jun and fos constitute multigene families; three and four different members, respectively, have been identified for each of them: c-jun, junB, and junD, and c-fos,fosB,fral, andfra2 (reviewed by Vogt and Bos [53] 
MATERIALS AND METHODS
Cell culture, transfections, and CAT assays. C33, HaCaT (7), and HeLa cells were grown in Dulbecco's modified Eagle medium containing 7% fetal calf serum. Normal foreskin human keratinocytes were maintained as previously described (41) . Cells were kept in KGM medium and passaged by trypsinization followed by centrifugation through medium containing serum for trypsin inactivation. C33, F9, and HaCaT cells were transfected by the standard calcium phosphate coprecipitation technique (55) Jun and Fos expression plasmids were previously described (24) .
Nuclear extracts and gel shift assays. Nuclear extracts were prepared as previously described by Schreiber et al. (43) . Briefly, confluent cells from a 10-cm petri dish were scraped in 1 ml of Tris-buffered saline, pelleted, and then resuspended in 400 RI of a buffer containing 10 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES; pH 7.9), 10 of the antipeptide antiserum was added in the prcincubated nuclear extracts and further incubated at room temperaturc for 15 min before addition of the labelled probe and loading of the gels. Induction was done by incubation of the cell culture in the presence of 1 ng of TPA per ml for 5 h.
The various Jun and Fos RNAs were synthesized by using T7 expression plasmids and T7 RNA polymerase, and the proteins were synthesized with a rabbit reticulocyte lysatc system (Amersham N90) as described elsewhere (24) . For the Jun/Fos heterodimers, both Jun and Fos RNAs were translated totcther in the same reaction mixture to ensure better forma-in of the heterodimers.
Antisera. Anti-Jun rabbit polyclonal antibodies were generated against the following peptides: c-Jun, SYGAAGLAF PSQPQQ; JunB, ISYLPHAPPFAGG; and JunD, GCQ LLPQHQVPAY. These peptides are 100% homologous in mouse and human Jun proteins for JunB and JunD. For c-Jun, only one amino acid differs in the 15-amino-acid-long peptide (S versus A at position 11). Prior to supershift experiments, the antisera were precipitatcd by ammonium sulfate.
Western blotting. Ten micrograms of nuclear extracts from HaCaT cells or primary human keratinocytes was fractionated on denaturing polyacrylamide gels and analyzed with specific antibodies after Western blot as previously described (13) . Cell cultures were treated for 5 h with 1 ng of TPA per ml.
RESULTS
Mutations in the putative API binding sites of the HPV-18 regulatory region. Mutations were introduced into the 230-bp proximal fragment of the P105 promoter in the CAT expression plasmid p18/42, which contains the entire long control region (LCR) of HPV-18 cloned in front of the bacterial CAT gene (50) . Mutations of the wild-typc 5'-TGACTAA-3' sequence to 5'-TAAGTAA-3' were introduced in the proximal API binding site, 171 nt upstream of the P105 initiation sitc, by reconstructions with combinations of oligonucleotides as previously described (37, 51) . Identical mutations were made in the distal AP1 binding site 5'-TTAGTCA-3', which is the same sequence as the proximal 5'-TGACTAA-3' on the opposite DNA strand, 349 nt upstream of the P1(5 initiation site, by polymerase chain reaction amplification using a 60-nt-long primer containing mutations in the overlapping API binding sequence as shown in Fig. 1 (20) and the TATA box are indicated. The two horizontal black bars indicate putative glucocorticoid-responsive elements (GRE?) (10) , and the gray ovals represent putative OCT1-binding elements (16, 38) . The two putative AP1 binding sites (17) are represented by triangles. The 230-bp fragment (nt 5709 to 7739) that has been shown to contain an intrinsic enhancer activity restricted to human epithelial cells (49) lines. The activities of the four CAT plasmids described above were studied in the C33 and HeLa cervical carcinomaderived cell lines, in the HaCaT keratinocyte cell line, and in normal human keratinocyte cultures. The activity of the reconstructed wild-type HPV-18 LCR plasmid was similar to the activity of the original wild-type expression plasmid p18/42 (51) , which represents about 10% of the transcriptional activity of the SV40 early promoter-CAT plasmid. As shown in Fig. 2 (Fig. 3A and B) . When cloned in a reporter plasmid upstream of the thymidine kinase (TK) promoter, the A18 sequences increased the activity of the TK promoter in a variety of cell lines, including the cervical carcinoma cell lines and keratinocytes examined in this study (results not shown).
Cotransfections of the mouse F9 cell line, which expresses very low levels of endogenous Jun, with these plasmids and the three Jun expression plasmids together with a c-Fos expression plasmid resulted in a 30-fold activation of transcription of the TK promoter in the presence of five copies of the A18 binding sequences (Fig. 4) . It is interesting to note that in the same cell line under similar experimental conditions, the HPV-18 P105 promoter was completely inactive and could not be activated by the various combinations of the Jun and Fos products. The differences could not be attributed to the number of copies of the A18 AP1 cis elements in the two promoters (two versus five), since TK chimeric plasmids, with one or two AP1 binding sites, were Characterization of the specificity of the Jun antipeptide antisera. To examine the identity of the Jun product(s) present in nuclear extracts from keratinocytes and cervical carcinoma cell lines, we used antipeptide antisera. Rabbit polyclonal antibodies were raised against peptides unique to each of the three different mouse Jun proteins, c-Jun, JunB, and JunD. The amino acid sequences used are identical in the homologous human Jun proteins. The supershift experiments shown in Fig. 3C demonstrate the specificity of each antipeptide antiserum to its corresponding in vitro-translated Jun protein, since no cross-reactions could be detected. Efficiencies of the supershifts, however, were variable. While the interaction of the shifted complex containing JunD with its specific antiserum led to its complete disappearance, with part of the complex being supershifted high in the gel, the two other antisera were less efficient, and increased volumes of antiserum were necessary to fully shift the DNA/protein complexes. In both cases, however, a clear decrease in the intensity of the shifted complexes, after incubation with the specific antisera, was detected along with a partial supershift. These quantitative differences in the supershifts of in vitro DNA/protein-bound complexes could be due to a number of factors, including the affinity (Fig. 5 and results not shown) . Upon TPA treatment, this specific binding to the AP1 probe increased three-to fourfold in the HaCaT cell line. This increase was specific for the complex bound to the A18 sequence, since no change in the amount of complex bound to an SP1 probe could be detected upon identical experimental conditions (Fig. 5) .
The specific antipeptide antibodies were used in gel shift experiments to determine the type of Jun present in the AP1 complexes binding A18. With the human HaCaT keratinocytes, the JunB antipeptide antiserum significantly displaced part of the complex (Fig. 6B) . A clear decrease in the intensity of the retarded band was reproducibly observed, which corresponded to more than half of the total shifted complex, regardless of whether the cells were TPA treated ( Fig. 6B and results not shown) . Although very faint, the supershifted band was often visible (arrow in Fig. 6A ). In contrast, with the c-Jun antipeptide antibody, no decrease in the intensity of the bound complex and no appearance of a supershifted complex could be detected. A slight but reproducible decrease was observed with the anti JunD antipep- tide antibody. When both anti-JunB and anti-JunD antibodies were used together, the retarded complex was almost completely displaced (Fig. 6) . We conclude from these experiments that JunB is the predominant Jun component associated with Fos in human keratinocytes. Only a small portion of the bound complex could be attributed to JunD, and little or no c-Jun could be detected.
In the HPV-negative cervical carcinoma cell line C33, the AP1 complex bound to A18 sequence was very faint, about 20 times less abundant than in keratinocytes when compared with the binding of an SP1 probe (Fig. 5) . TPA treatment induced a severalfold increase in DNA binding specifically to the A18 probe compared with the SP1 probe (Fig. 5) . Studies using the antipeptide antibodies (not shown) indicated that the retarded complex was more clearly displaced by both antipeptide C and antipeptide D and less by antipeptide B.
However, it was very difficult to define a precise pattern of Jun expression in this cell line, and we tentatively propose that the three Jun factors are expressed at low levels in this cell line. In contrast, we found that keratinocyte cell lines transformed by HPV-18 or by the SV40 T antigen, as well as the cervical carcinoma cell line HeLa, which contains HPV-18 sequences, exhibited high levels of JunB, although c-Jun and JunD were also present (data not shown).
To confirm the predominance of JunB in keratinocytes, we examined the Jun proteins present in nuclear extracts prepared from HaCaT cells or from normal foreskin human keratinocytes by Western blot analysis. The JunB antipep- tide antiserum revealed a detectable band in these cells which was further increased by TPA treatment (Fig. 7) . A faint band could also be seen with JunD antipeptide antibody, with a weaker activation by TPA. c-Jun could not be detected in these extracts (results not shown). Western blots using nuclear extracts from NIH 3T3 cells have indicated that the three Jun antipeptide antibodies were able to detect their corresponding Jun product with similar efficiencies (results not shown). These results are consistent with those of the antibody supershift experiments shown in Fig. 6 and implicate JunB in the regulation of HPV-18 P1os promoter transcription in human keratinocytes, since it is the Jun family member present at a high level in these cells.
DISCUSSION
Transcription of the HPV-18 P105 promoter, which controls expression of the E6 and E7 transforming genes, is regulated by a combination of viral and cellular factors. This transcription depends upon keratinocyte differentiation in a way that is not yet understood. This very tight relationship between viral gene expression and cell differentiation is reflected by the cell specificity of the P105 promoter, which is active only in certain human epithelial cells. We show here that the ubiquitous transcription factor AP1 is essential for the activity of this promoter. Mutations despite their different locations within the control region, one site being located in the cell-type-specific enhancer (Fig.  1) . Multiple molecular species constitute the AP1 factor, which has been implicated in the control of fibroblast proliferation. The fact that different combinations of Jun homodimers or of Jun/Fos heterodimers can be formed in the cell and bind to the same cognate sequence creates an important diversity. The three members of the Jun family, c-Jun, JunB, and JunD, were described in, and isolated from, mouse cells (25, 29, 39, 40) and human cells (1, 3, 6, 45) . The different members of the Jun family are coexpressed in many tissues, although at different levels. The three Jun proteins, c-Jun, JunB, and JunD, have about 50% overall homology, and their N-terminal regions contain the transcriptional activation domains (24) . As heterodimers with Fos, these three Jun products appear to be comparably efficient transcriptional transactivators. The finding that the jun genes differ in their sites of expression in adult mice (23, 39) raises the possibility that their products contribute to tissue-specific expression of target genes regulated by AP1.
Here The importance of AP1 in the keratinocyte-specific transcriptional activity of P105 was suggested by results of an in vitro transcription study (34) . The authors concluded from their experiments that AP1 was more abundant in extracts from human epithelial cells than in extracts from fibroblasts in which the promoter is inactive and that these quantitative differences would explain the cell specificity. We show in this study that despite a low amount of AP1, the P105 promoter is active in the C33 cell line, while it is inactive in F9 cells expressing excess AP1, indicating that quantitative differences are not sufficient to explain the cell type specificity. More (Fig. 1) . The regulation of the HPV-18 P105 promoter by glucocorticoid hormones is not well understood, but the negative interference between steroid hormone receptors and AP1 has been documented in other systems (13, 26, 30, 44, 57) . We cannot rule out the possibility of such a negative interference for P105 regulation.
The E6 and E7 RNAs, which code for the two viral oncoproteins, are transcribed from the HPV-18 P105 promoter. HPV infection induces cell proliferation which is probably due, at least in part, to specific interactions of the viral E6 and E7 products with the cellular p53 and Rb proteins, respectively (14, 32, 33, 54) . On the other hand, cell proliferation is associated with elevated AP1 activity, which will activate promoters containing APi-responsive elements (8, 27) . It is therefore probable that cell proliferation, induced by E6/E7 gene expression will, in turn, activate AP1, which is a positive transactivator of E6/E7 P105 promoter transcription, thus creating a positive regulatory loop during the viral cycle.
